Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Jan 22, 2024

SELL
$0.15 - $0.4 $5,250 - $14,000
-35,000 Reduced 77.78%
10,000 $2,000
Q3 2023

Oct 13, 2023

SELL
$0.2 - $2.08 $1,180 - $12,272
-5,900 Reduced 11.59%
45,000 $9,000
Q2 2023

Jul 19, 2023

BUY
$2.0 - $3.2 $42,000 - $67,200
21,000 Added 70.23%
50,900 $104,000
Q1 2023

Apr 11, 2023

SELL
$1.43 - $3.3 $33,748 - $77,880
-23,600 Reduced 44.11%
29,900 $98,000
Q4 2022

Jan 09, 2023

SELL
$1.37 - $4.42 $22,605 - $72,930
-16,500 Reduced 23.57%
53,500 $0
Q3 2022

Oct 04, 2022

BUY
$2.55 - $4.42 $178,500 - $309,400
70,000 New
70,000 $20,000

Others Institutions Holding BCLI

About BRAINSTORM CELL THERAPEUTICS INC.


  • Ticker BCLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,486,200
  • Market Cap $42.7M
  • Description
  • Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem ...
More about BCLI
Track This Portfolio

Track Weaver Consulting Group Portfolio

Follow Weaver Consulting Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Weaver Consulting Group, based on Form 13F filings with the SEC.

News

Stay updated on Weaver Consulting Group with notifications on news.